Investigational Drug Details
| Drug ID: | D185 |
| Drug Name: | Stavudine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00649 |
| DrugBank Description: | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. |
| PubChem ID: | 18283 |
| CasNo: | 3056-17-5 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O |
| Structure: |
|
| InChiKey: | XNKLLVCARDGLGL-JGVFFNPUSA-N |
| Molecular Weight: | 224.2133 |
| DrugBank Targets: | Reverse transcriptase/RNaseH |
| DrugBank MoA: | Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. |
| DrugBank Pharmacology: | Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. |
| DrugBank Indication: | For the treatment of human immunovirus (HIV) infections. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|